Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership
Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership
复制标题
DOI：
10.1007/s11414-018-9616-9
复制
发表时间：
2019-04-01
影响因子：
1.9
通讯作者：
Schmidt, Laura
中科院分区：
文献类型：
--
作者：
Croff, Raina;Hoffman, Kim;Schmidt, Laura
药物治疗包括越来越多的临床有效的药物治疗物质使用障碍，但在常规临床实践中采用和实施存在重大障碍。药物研究伙伴关系（MRP）是一项成功的努力，促进在9个药物滥用治疗中心和商业健康计划中采用阿片类药物和酒精使用障碍的药物治疗。在基线和6个月变化周期结束/开始时对变革领导者进行的访谈（n=39）的定性分析解释了治疗中心如何克服药物治疗的采用，实施和可持续性的障碍。结果表明，通过对组织变革策略的增量测试，并辅以专家指导和志同道合的专业人士的学习社区，可以克服采用、实施和维持药物治疗的障碍。最大的挑战在于克服禁欲哲学，建立药物治疗的商业案例，并与付款人和制药代表合作。
Pharmacotherapy includes a growing number of clinically effective medications for substance use disorder, yet there are significant barriers to its adoption and implementation in routine clinical practice. The Medication Research Partnership (MRP) was a successful effort to promote adoption of pharmacotherapy for opioid and alcohol use disorders in nine substance abuse treatment centers and a commercial health plan. This qualitative analysis of interviews (n=39) conducted with change leaders at baseline and at the end/beginning of 6-month change cycles explains how treatment centers overcame obstacles to the adoption, implementation, and sustainability of pharmacotherapy. Results show that barriers to adopting, implementing, and sustaining pharmacotherapy can be overcome through incremental testing of organizational change strategies, accompanied by expert coaching and a learning community of like-minded professionals. The greatest challenges lie in overcoming abstinence-only philosophies, establishing a business case for pharmacotherapy, and working with payers and pharmaceutical representatives.